DBV Technologies (DBVT), a late-stage biopharmaceutical company, is scheduled to present additional data from its positive VITESSE phase 3 study on Feb.28, 2026.
VITESSE is a pivotal phase 3 study assessing the safety and efficacy of VIASKIN Peanut patch for the treatment of peanut-allergic children aged 4 to 7 years. The company reported positive topline results from the study last December.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.